Physician profile
Bernadett G Kohn
NPI 1851485346
$5,721.19
in general payments reported to CMS, 2019-2025
36 companies · $944 in 2025
The $944 reported for 2025 was more than what 85% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $1,002 · 2021: $1,308 · 2022: $518 · 2023: $739 · 2024: $554 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,236.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $789.06 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $488.75 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $488.63 | 2019-2022 | |
| Pfizer INC. | $338.28 | 2023-2025 | |
| Lundbeck LLC | $283.25 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $257.08 | 2019-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $253.28 | 2020-2025 | Austedo Xr |
| Corium, LLC | $231.45 | 2022-2024 | Azstarys |
| Allergan, INC. | $215.43 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $209.09 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $185.86 | 2020-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $179.50 | 2019-2023 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $161.63 | 2019-2025 | |
| Adlon Therapeutics L.P. | $138.66 | 2019-2021 | |
| Tris Pharma INC | $131.89 | 2020-2025 | Dyanavel Xr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $124.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $116.31 | 2022 | |
| Lilly USA, LLC | $113.59 | 2019-2025 | Kisunla, Amyvid |
| Alkermes, INC. | $96.47 | 2019-2024 | Aristada, Lybalvi |
| Bausch Health US, LLC | $94.85 | 2020-2023 | Aplenzin, Wellbutrin |
| Neos Therapeutics, Lp | $89.98 | 2019-2025 | Adzenys Xr-Odt |
| Shire North American Group INC | $88.94 | 2019 | |
| Ucb, INC. | $77.05 | 2021 | |
| Biogen, INC. | $74.37 | 2025 | Zurzuvae |
| Amgen INC. | $73.81 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.43 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $66.85 | 2019-2022 | |
| Livanova USA, INC. | $63.67 | 2020-2021 | |
| Harmony Biosciences LLC | $62.36 | 2023-2024 | Wakix |
| Idorsia Pharmaceuticals US INC | $34.61 | 2023-2025 | Quviviq, Quviviq |
| Rhodes Pharmaceuticals L.P. | $30.22 | 2019 | |
| Axsome Therapeutics, INC. | $24.03 | 2025 | Sunosi |
| Vanda Pharmaceuticals INC. | $20.80 | 2019 | |
| Impel Pharmaceuticals INC. | $17.61 | 2023 | Trudhesa |
| Avanir Pharmaceuticals, INC. | $16.59 | 2020 | |
| Merck Sharp & Dohme LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadett Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.